Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decoding BRCA1 and BRCA2 Mutations in High-Grade Serous Ovarian Cancer: Impact of Location and Type of Mutation on Prognosis and PARP Inhibitor Treatment.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society - 1 Jun 2026

Momi Marina, Salviato Elisa, Ravaggi Antonella, Mazza Cinzia, Tognon Germana, Bergamaschi Cosetta, Zanotti Laura, Gozzini Elisa, Zizioli Valentina, Odicino Franco, Bignotti Eliana

Abstract excerpt

OBJECTIVE: Pathogenic mutations in BRCA1/2 are associated with improved survival in high-grade serous ovarian carcinoma, but the prognostic impact of specific mutations remains unclear. The primary aim of this study was to evaluate the role of different locations, types, and functions of BRCA1/2 mutations on survival in patients with high-grade serous ovarian carcinoma. METHODS: This study included a total of 174...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Cystadenocarcinoma, Serous

Share to Neoplasm Grading

Share to Ovarian Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Prognosis

Source

Identifiers

PMID: 42061278
DOI: 10.1016/j.ijgc.2026.104679

Genes

BRCA1
BRCA2
RAD51

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decoding BRCA1 and BRCA2 Mutations in High-Grade Serous Ovarian Cancer: Impact of Location and Type of Mutation on Prognosis and PARP Inhibitor Treatment.PMID 42061278Read ↗

Critical molecular abnormalities in high-grade serous carcinoma of the ovary.Semantic proximity Read ↗

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.Semantic proximity Read ↗

The Changing View of High-Grade Serous Ovarian CancerSemantic proximity Read ↗

A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.Semantic proximity Read ↗

Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation typeSemantic proximity Read ↗

Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpointsSemantic proximity Read ↗

BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients.Semantic proximity Read ↗

Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer.Semantic proximity Read ↗

BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar populationSemantic proximity Read ↗

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.Semantic proximity Read ↗

Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinomaSemantic proximity Read ↗

Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 MutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.